Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of inactivated SARS-CoV-2 vaccine (Vero cell)
ChiCTR2000034780Phase 3Completed
- Sponsor
- China National Biotec Group
- Start
- Jul 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of inactivated sars-cov-2 vaccine (vero cell) in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by China National Biotec Group. Primary endpoint: Protective efficacy against COVID-19. Started Jul 2020; status: completed.
02
Drugs
inactivated sars-cov-2 vaccine (vero cell)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000034780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034780.